The Update Transforms Pharmaceutical Websites From Static Information Hubs into User-Friendly, Responsive, and Intelligent Digital Tools

Ostro, the only customer-facing agentic AI platform built for the life sciences industry, today launched a new unified digital experience to power its flagship engagement tools, Tailor and Navigate. Designed to help healthcare providers (HCPs) and patients more quickly access relevant and reliable medical information, the enhanced experience effectively combines the capabilities of Ostro’s conversational AI chat tool and its advanced search function into a single seamless interface.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250925144772/en/

AI Conversation

Research shows that two out of three HCPs are already using AI to support their daily workflows. At the same time, more than 15 percent of all patients are already using AI tools like ChatGPT for medical advice. As AI adoption increases among HCPs and patients alike, so do the expectations for usability, personalization, and clarity.

Now, with Ostro’s unified digital experience, drug manufacturers can provide compliant and actionable answers to their website users' complex pharmaceutical questions, keeping pace with the evolving healthcare landscape. This is incredibly important for life sciences as clarity, compliance, and speed are essential. With LLMs like ChatGPT proven to be unreliable sources of medical advice and information, Ostro’s AI tools boast an impressive 0 percent hallucination rate while remaining in line with evolving FDA guidelines and have been proven to outperform traditional bots and enterprise search tools.

“Ostro’s entire suite of products was purpose-built for the unique needs of the life sciences industry,” said Gurjeev Singh, Head of Product at Ostro. “Executing effective go-to-market and brand strategies starts with an understanding of the challenges facing your target audience. With this enhanced experience, HCPs no longer have to dreadfully sift through packets of information to make the best treatment decision, and patients benefit from immediate access to valuable tools and resources like savings cards and pharmacy locators.”

The platform redesign was developed through extensive user research, behavioral analytics, and competitive benchmarking. Through this work, alongside its partnerships with ten of the top 20 global pharmaceutical companies, Ostro uncovered the need for greater clarity, utility, and efficiency in the way both HCPs and patients engage with brand websites.

“This project helped us rethink how AI shapes engagement. We’re aiming to meet customers where they are, with the clarity, speed, and convenience they need,” said Matt Balogh, Head of Digital Marketing at Melinta Therapeutics. “Ostro’s platform flips traditional digital engagement on its head — not just more clicks and time-on-site, but real answers, faster. Their team has been knowledgeable, flexible, and collaborative throughout. They’ve been true partners in shaping how we approach AI.”

The news of this product enhancement comes on the heels of Ostro announcing the launch of Airmark, a first-of-its-kind solution that turns static one-way emails to healthcare professionals (HCPs) into responsive, compliant two-way conversational AI. For more information on Ostro and its AI-powered omnichannel ecosystem of solutions for life sciences, please visit ostrohealth.com.

About Ostro

Ostro is a leader in AI-powered digital engagement solutions, dedicated to helping life sciences brands create meaningful interactions that drive better outcomes. Through its innovative technology, Ostro enables organizations to connect with patients, caregivers, and healthcare providers in personalized, impactful, and compliant ways.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250925144772/en/